Advertisement

European Journal of Epidemiology

, Volume 21, Issue 11, pp 843–845 | Cite as

Response to influenza vaccine in people with non-protective HI antibody titers

  • Vincenzo Baldo
  • Tatjana Baldovin
  • Annarosa Floreani
  • Michele Minuzzo
  • Renzo Trivello
Letter to the Editor

Abstract

The purpose of the study was to determine which factors correlate directly with response to vaccination in such a group of subjects with non-protective HI antibody titers before vaccination. Two vaccines were used, a subunit virus vaccine adjuvanted with MF59 and a split virus vaccine. The analysis indicated that immunization with vaccine adjuvanted with MF59 was an independent variable for immune response against A/H3N2 (OR: 3.51; 95% CI: 1.81–6.79) and B (OR: 2.31; 95% CI: 1.37–3.89). The results suggest that antibody response to vaccine is satisfactory in elderly people previously lacking a protective antibody titer, and that the adjuvanted vaccine reveals a better immunogenicity.

Keywords

Antibody response Influenza MF59 Vaccine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vu T, farish S, Jenkins M, Kelly H (2002) A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831–1836PubMedCrossRefGoogle Scholar
  2. 2.
    De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus ADME (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115:63–73Google Scholar
  3. 3.
    Remarque EJ, De Jong JM, Van Der Klis RJ, Masurel N, Ligthart GJ (1999) Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol: 34:109–115CrossRefGoogle Scholar
  4. 4.
    Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R (1999) Influenza vaccines: antibody responses to split MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 15:573–576PubMedCrossRefGoogle Scholar
  5. 5.
    Beyer WEP, Palache AM, Osterhaus ADME (1998) Comparison of serology and reactogenicity between influenza subunit vaccine and whole virus or split virus: a review and meta-analysis of the literature. Clin Drug Invest 15:1–12Google Scholar
  6. 6.
    Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus ADME (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103:125–132PubMedCrossRefGoogle Scholar
  7. 7.
    Potter CW (2001) A history of influenza. J Appl Microbiol 91:572–579PubMedCrossRefGoogle Scholar
  8. 8.
    Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937–1943PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Vincenzo Baldo
    • 1
  • Tatjana Baldovin
    • 1
  • Annarosa Floreani
    • 2
  • Michele Minuzzo
    • 1
  • Renzo Trivello
    • 1
  1. 1.Department of Environmental Medicine and Public Health, Institute of HygieneUniversity of PaduaPadovaItaly
  2. 2.Department of Surgical and Gastroenterological SciencesUniversity of PadovaPadovaItaly

Personalised recommendations